We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

64 hedge funds and large institutions have $665M invested in 4D Molecular Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

23% more funds holding

Funds holding: 52 → 64 (+12)

10% more capital invested

Capital invested by funds: $602M → $665M (+$62.2M)

2.55% more ownership

Funds ownership: 55.09% → 57.64% (+2.6%)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

Holders
64
Holders Change
+12
Holders Change %
+23.08%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
28
Increased
13
Reduced
13
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$24M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$18.9M
3
ACM
Aquilo Capital Management
California
+$12.4M
4
LCM
Laurion Capital Management
New York
+$9.67M
5
CC
Casdin Capital
New York
+$9.51M

Top Sellers

Rank Fund Capital Flow
1
SM
SB Management
United Arab Emirates
-$16.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.6M
3
PA
Perceptive Advisors
New York
-$6.88M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.27M
5
O
OrbiMed
New York
-$5.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
51
MetLife Investment Management
New Jersey
$177K +$181K +4,083 New
New York State Common Retirement Fund
52
New York State Common Retirement Fund
New York
$152K +$155K +3,500 New
MLICM
53
Metropolitan Life Insurance Company (MetLife)
New York
$129K +$132K +2,984 New
Wells Fargo
54
Wells Fargo
California
$106K +$108K +2,440 New
SO
55
STRS Ohio
Ohio
$82K +$84.1K +1,900 New
Citigroup
56
Citigroup
New York
$59K +$60.6K +1,368 New
Legal & General Group
57
Legal & General Group
United Kingdom
$34K +$35.1K +792 New
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$31K +$31.6K +713 New
AIP
59
Ameritas Investment Partners
Nebraska
$27K +$28K +633 New
TRCT
60
Tower Research Capital (TRC)
New York
$26K +$26.8K +604 New
EWA
61
Evolution Wealth Advisors
Florida
$12K +$12.7K +286 New
Bank of Montreal
62
Bank of Montreal
Ontario, Canada
$10K +$10.8K +244 New
NFSG
63
Newbridge Financial Services Group
Florida
$1K +$1.33K +30 New
AIG
64
American International Group
New York
$197 +$201K +4,535 New
O
65
OrbiMed
New York
– -$5.18M -125,000 Closed
FCM
66
Farallon Capital Management
California
– -$4.14M -100,000 Closed
JGC
67
J. Goldman & Co
New York
– -$2M -48,287 Closed
MWNA
68
Marshall Wace North America
New York
– -$1.49M -35,825 Closed
SG Americas Securities
69
SG Americas Securities
New York
– -$1.4M -33,680 Closed
ECM
70
ExodusPoint Capital Management
New York
– -$1.37M -33,152 Closed
PCM
71
Pinz Capital Management
New York
– -$825K -19,900 Closed
Qube Research & Technologies (QRT)
72
Qube Research & Technologies (QRT)
United Kingdom
– -$684K -16,496 Closed
Mirae Asset Global Investments
73
Mirae Asset Global Investments
South Korea
– -$498K -12,000 Closed
MIM
74
Monashee Investment Management
Massachusetts
– -$415K -10,000 Closed
MFS
75
Mirabella Financial Services
United Kingdom
– -$345K -8,330 Closed
1 2
3
4

FDMT Hedge Fund Activity: Q1 2021 in Review

64 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2021, worth a combined $665M — up 10% from $602M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new FDMT positions and 16 closed out — a net gain of 12 holders — while 13 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $24M. The largest seller was SB Management, cutting an estimated $16.4M.

  • 64 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2021, up from 52 in Q4 2020.
  • Funds reported $665M of 4D Molecular Therapeutics stock for Q1 2021, up 10% quarter-over-quarter.
  • 28 funds opened new 4D Molecular Therapeutics positions in Q1 2021 and 16 closed out, a net change of +12 holders.
  • The largest 4D Molecular Therapeutics buyer in Q1 2021 was BlackRock, an estimated $24M added.
  • The largest 4D Molecular Therapeutics seller in Q1 2021 was SB Management, an estimated $16.4M sold.

Based on aggregated 13F filings for Q1 2021.